EP3193857A4 - Abiraterone acetate formulation and methods of use - Google Patents

Abiraterone acetate formulation and methods of use Download PDF

Info

Publication number
EP3193857A4
EP3193857A4 EP15842591.8A EP15842591A EP3193857A4 EP 3193857 A4 EP3193857 A4 EP 3193857A4 EP 15842591 A EP15842591 A EP 15842591A EP 3193857 A4 EP3193857 A4 EP 3193857A4
Authority
EP
European Patent Office
Prior art keywords
methods
abiraterone acetate
acetate formulation
formulation
abiraterone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15842591.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3193857A1 (en
Inventor
Maura Murphy
Paul NEMETH
H. William Bosch
Matthew CALLAHAN
Satya Bhamidipati
Jason Coleman
Christopher Hill
Marck Norret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sun Pharma Global FZE
Original Assignee
Iceutica Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55533897&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP3193857(A4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US14/707,922 external-priority patent/US20150246060A1/en
Application filed by Iceutica Inc filed Critical Iceutica Inc
Publication of EP3193857A1 publication Critical patent/EP3193857A1/en
Publication of EP3193857A4 publication Critical patent/EP3193857A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
EP15842591.8A 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use Withdrawn EP3193857A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462052294P 2014-09-18 2014-09-18
US14/707,922 US20150246060A1 (en) 2013-03-15 2015-05-08 Abiraterone Acetate Formulation and Methods of Use
PCT/US2015/050889 WO2016044701A1 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Publications (2)

Publication Number Publication Date
EP3193857A1 EP3193857A1 (en) 2017-07-26
EP3193857A4 true EP3193857A4 (en) 2018-04-11

Family

ID=55533897

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15842591.8A Withdrawn EP3193857A4 (en) 2014-09-18 2015-09-18 Abiraterone acetate formulation and methods of use

Country Status (17)

Country Link
EP (1) EP3193857A4 (enExample)
JP (1) JP2017528457A (enExample)
KR (2) KR102491439B1 (enExample)
CN (1) CN106687112A (enExample)
AP (1) AP2017009804A0 (enExample)
AU (1) AU2015317466A1 (enExample)
BR (1) BR112017003219A2 (enExample)
CA (1) CA2958316A1 (enExample)
CO (1) CO2017002472A2 (enExample)
EA (1) EA201790650A1 (enExample)
IL (1) IL250270B (enExample)
MD (1) MD20170048A2 (enExample)
MX (1) MX2017003525A (enExample)
PH (1) PH12017500239A1 (enExample)
SG (1) SG11201701139YA (enExample)
TN (2) TN2017000098A1 (enExample)
WO (1) WO2016044701A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280448B1 (en) 2015-04-10 2020-12-30 Capsugel Belgium NV Abiraterone acetate lipid formulations
WO2018187728A1 (en) 2017-04-07 2018-10-11 Maa Laboratories, Inc. Methods of improving the solubility and bioavailability of therapeutic agents
EP3914234A4 (en) * 2019-01-25 2022-09-14 Shenzhen Pharmacin Co., Ltd. PHARMACEUTICAL COMPOSITIONS
DK3935068T3 (da) 2019-03-06 2023-12-04 Propella Therapeutics Inc Abirateron-prodrugs
CN110742870B (zh) * 2019-12-04 2021-04-20 武汉大学 醋酸阿比特龙制剂及其制备方法
CN111110646A (zh) * 2020-02-19 2020-05-08 纳兰迦(上海)生物医药科技有限公司 一种低规格醋酸阿比特龙口服制剂的处方及制备方法
CN113384542B (zh) * 2020-03-14 2024-03-29 鲁南制药集团股份有限公司 一种甾体cyp17抑制剂固体分散体的片剂及其制备方法
US20230158047A1 (en) * 2020-04-16 2023-05-25 Tavanta Therapeutics Hungary Incorporated Methods and compositions for treating prostate cancer
WO2021224471A1 (en) * 2020-05-08 2021-11-11 Janssen Pharmaceutica Nv Pharmaceutical formulations of abiraterone acetate and niraparib
EP3944860A1 (en) 2020-07-30 2022-02-02 Galenicum Health S.L.U. Abiraterone for use in a method of treating cancer
WO2022174134A1 (en) 2021-02-15 2022-08-18 Propella Therapeutics, Inc. Abiraterone prodrugs
KR20240044329A (ko) 2022-09-28 2024-04-04 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
KR20240145412A (ko) 2023-03-27 2024-10-07 한미약품 주식회사 아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164473A1 (en) * 2012-05-04 2013-11-07 Jagotec Ag Pharmaceutical composition comprising abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014145813A1 (en) * 2013-03-15 2014-09-18 Iceutica Inc. Abiraterone acetate formulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ595984A (en) * 2009-04-24 2014-04-30 Iceutica Pty Ltd Production of encapsulated nanoparticles at commercial scale
WO2014009436A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Nanosuspension of abiraterone acetate
WO2014009434A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
CN102743393A (zh) * 2012-07-27 2012-10-24 海南盛科生命科学研究院 一种含有醋酸阿比特龙的药物组合物及制备工艺

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013164473A1 (en) * 2012-05-04 2013-11-07 Jagotec Ag Pharmaceutical composition comprising abiraterone acetate
WO2014009437A1 (en) * 2012-07-11 2014-01-16 Sandoz Ag Oxidation stability of abiraterone acetate
WO2014145813A1 (en) * 2013-03-15 2014-09-18 Iceutica Inc. Abiraterone acetate formulation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2016044701A1 *

Also Published As

Publication number Publication date
KR102491439B1 (ko) 2023-01-25
MX2017003525A (es) 2017-06-21
PH12017500239A1 (en) 2017-07-03
KR102617537B1 (ko) 2023-12-22
EP3193857A1 (en) 2017-07-26
SG11201701139YA (en) 2017-03-30
AU2015317466A1 (en) 2017-02-23
KR20230014878A (ko) 2023-01-30
MD20170048A2 (ro) 2017-08-31
JP2017528457A (ja) 2017-09-28
CO2017002472A2 (es) 2017-07-11
BR112017003219A2 (pt) 2017-11-28
AP2017009804A0 (en) 2017-03-31
IL250270B (en) 2021-02-28
IL250270A0 (en) 2017-03-30
CA2958316A1 (en) 2016-03-24
TN2017000098A1 (en) 2018-10-19
CN106687112A (zh) 2017-05-17
WO2016044701A1 (en) 2016-03-24
KR20170070025A (ko) 2017-06-21
TN2018000318A1 (en) 2020-01-16
EA201790650A1 (ru) 2017-07-31

Similar Documents

Publication Publication Date Title
EP3193857A4 (en) Abiraterone acetate formulation and methods of use
EP3209308A4 (en) Activated bifidobacteria and methods of use thereof
EP3245291A4 (en) Novel micro-dystrophins and related methods of use
EP3157528A4 (en) Oxysterols and methods of use thereof
EP3377070A4 (en) COMPOUNDS AND METHOD FOR THEIR USE
EP3194525A4 (en) Proppant compositions and methods of use
EP3218005A4 (en) Glycan-interacting compounds and methods of use
EP3092001A4 (en) Immunomodulatory compositions and methods of use thereof
EP4599887A3 (en) Oxysterols and methods of use thereof
EP3145442A4 (en) Intraoral device and method of use
EP3116511A4 (en) Compositions of selenoorganic compounds and methods of use thereof
EP3131534A4 (en) Fucoidan nanogels and methods of their use and manufacture
EP3096715A4 (en) Bidirectional stent and method of use thereof
EP3310374A4 (en) GLUTATHION FORMULATION AND METHOD OF USE
EP3137096A4 (en) Enamel products and methods of use
EP3134088A4 (en) Bicylcic pyrazolone compounds and methods of use
EP3240576A4 (en) Methods of transdifferentiation and methods of use thereof
EP3190886A4 (en) Compositions and methods of use thereof
EP3226955A4 (en) Self-anchoring catheters and methods of use
EP3185872A4 (en) Formulations of testosterone and methods of treatment therewith
EP3137873A4 (en) Viscometer and methods of use thereof
EP3221597A4 (en) Wall-mountable assembly and method of use
EP3128996A4 (en) Novel 7-Dehydrocholesterol Derivatives and Methods Using Same
EP3130340A4 (en) Isoacteoside derivative and preparation method and use thereof
EP3148456A4 (en) Adjustable cannula and methods of use

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20170418

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20180308

RIC1 Information provided on ipc code assigned before grant

Ipc: C07J 43/00 20060101ALI20180303BHEP

Ipc: A61K 31/19 20060101AFI20180303BHEP

Ipc: A61K 9/20 20060101ALI20180303BHEP

Ipc: A61P 13/08 20060101ALI20180303BHEP

Ipc: A61K 31/58 20060101ALI20180303BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1241293

Country of ref document: HK

17Q First examination report despatched

Effective date: 20190820

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SUN PHARMA GLOBAL FZE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20200103

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1241293

Country of ref document: HK